These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31200322)

  • 21. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.
    Nakazawa M; Lu C; Chen Y; Paller CJ; Carducci MA; Eisenberger MA; Luo J; Antonarakis ES
    Ann Oncol; 2015 Sep; 26(9):1859-1865. PubMed ID: 26117829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.
    de Wit R; Wülfing C; Castellano D; Kramer G; Eymard JC; Sternberg CN; Fizazi K; Tombal B; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Foster MC; Ozatilgan A; Geffriaud-Ricouard C; de Bono J
    ESMO Open; 2021 Oct; 6(5):100241. PubMed ID: 34450475
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
    N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO).
    Puente J; González-Del-Alba A; Sala-Gonzalez N; Méndez-Vidal MJ; Pinto A; Rodríguez Á; Cuevas Sanz JM; Muñoz Del Toro JR; Useros Rodríguez E; García García-Porrero Á; Vázquez S
    BMC Cancer; 2019 Aug; 19(1):766. PubMed ID: 31382926
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
    Scher HI; Lu D; Schreiber NA; Louw J; Graf RP; Vargas HA; Johnson A; Jendrisak A; Bambury R; Danila D; McLaughlin B; Wahl J; Greene SB; Heller G; Marrinucci D; Fleisher M; Dittamore R
    JAMA Oncol; 2016 Nov; 2(11):1441-1449. PubMed ID: 27262168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.
    Wyatt AW; Azad AA; Volik SV; Annala M; Beja K; McConeghy B; Haegert A; Warner EW; Mo F; Brahmbhatt S; Shukin R; Le Bihan S; Gleave ME; Nykter M; Collins CC; Chi KN
    JAMA Oncol; 2016 Dec; 2(12):1598-1606. PubMed ID: 27148695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial.
    Brighi N; Conteduca V; Gurioli G; Scarpi E; Cursano MC; Bleve S; Lolli C; Schepisi G; Casadei C; Gianni C; Ulivi P; De Giorgi U
    ESMO Open; 2023 Dec; 8(6):102036. PubMed ID: 37866028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A; von Felten S; Vogt DR; Liewen H; de Wit R; de Bono J; Sartor O; Stenner-Liewen F
    Eur J Cancer; 2016 Mar; 56():93-100. PubMed ID: 26829012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activity of cabazitaxel in patients with metastatic castration-resistant prostate cancer after treatment with single or dual regimens of novel androgen receptor-targeting agents.
    Bando Y; Hinata N; Terakawa T; Furukawa J; Harada KI; Nakano Y; Fujisawa M
    Med Oncol; 2017 Aug; 34(9):163. PubMed ID: 28819719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ; Nieuweboer AJ; de Morrée ES; Chitu D; Bergman AM; Goey SH; Bos MM; van der Meer N; Hamberg P; de Wit R; Mathijssen RH;
    Eur J Cancer; 2015 Nov; 51(17):2562-9. PubMed ID: 26278646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA).
    Mehra N; Dolling D; Sumanasuriya S; Christova R; Pope L; Carreira S; Seed G; Yuan W; Goodall J; Hall E; Flohr P; Boysen G; Bianchini D; Sartor O; Eisenberger MA; Fizazi K; Oudard S; Chadjaa M; Macé S; de Bono JS
    Eur Urol; 2018 Sep; 74(3):283-291. PubMed ID: 29500065
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review.
    von Hardenberg J; Schwartz M; Werner T; Fuxius S; Strauss A; Worst TS; Nuhn P; Bolenz C; Heinrich E
    Urol Int; 2017; 99(4):414-421. PubMed ID: 28700990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    De Laere B; Oeyen S; Mayrhofer M; Whitington T; van Dam PJ; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert EG; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff IE; van Dam V; Brouwer A; Goossens D; Heyrman L; Van den Eynden GG; Rutten A; Del Favero J; Rantalainen M; Rajan P; Sleijfer S; Ullén A; Yachnin J; Grönberg H; Van Laere SJ; Lindberg J; Dirix LY
    Clin Cancer Res; 2019 Mar; 25(6):1766-1773. PubMed ID: 30209161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. No significant impact of patient age and prior treatment profile with docetaxel on the efficacy of cabazitaxel in patient with castration-resistant prostate cancer.
    Kosaka T; Hongo H; Watanabe K; Mizuno R; Kikuchi E; Oya M
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1061-1066. PubMed ID: 30283980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    To SQ; Kwan EM; Fettke HC; Mant A; Docanto MM; Martelotto L; Bukczynska P; Ng N; Graham LK; Parente P; Pezaro C; Mahon K; Horvath L; Todenhöfer T; Azad AA
    Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
    Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.
    Scher HI; Graf RP; Schreiber NA; Jayaram A; Winquist E; McLaughlin B; Lu D; Fleisher M; Orr S; Lowes L; Anderson A; Wang Y; Dittamore R; Allan AL; Attard G; Heller G
    JAMA Oncol; 2018 Sep; 4(9):1179-1186. PubMed ID: 29955787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.